DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Consensus Target Price from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been given a consensus recommendation of “Hold” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.75.

Several equities research analysts recently issued reports on DBVT shares. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a report on Saturday, September 27th. Lifesci Capital upgraded shares of DBV Technologies to a “strong-buy” rating in a research report on Thursday, June 26th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 price target on shares of DBV Technologies in a research report on Thursday, June 26th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. Finally, Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th.

DBV Technologies Trading Up 7.1%

Shares of DBVT stock opened at $14.24 on Friday. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $15.14. The firm’s 50 day moving average is $9.83 and its 200 day moving average is $9.21. The stock has a market capitalization of $390.18 million, a P/E ratio of -2.99 and a beta of -0.45.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%.The company had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $0.64 million. As a group, equities analysts predict that DBV Technologies will post -7.05 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

Institutional investors have recently bought and sold shares of the stock. Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies in the 2nd quarter worth $340,000. Octagon Capital Advisors LP bought a new position in DBV Technologies in the 2nd quarter worth $9,315,000. MPM Bioimpact LLC bought a new position in DBV Technologies in the 2nd quarter worth $9,649,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the second quarter worth $9,659,000. Finally, Vivo Capital LLC purchased a new stake in shares of DBV Technologies in the second quarter worth $9,659,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.